Introduction KRAS mutation has long been considered a key oncogenic driver across multiple cancers, yet historically labeled “undruggable. ” Recent therapeutic breakthroughs have changed this paradigm, with KRAS inhibitors now emerging as viable treatment options.
Introduction
KRAS mutation has long been considered a key oncogenic driver across multiple cancers, yet historically labeled “undruggable.” Recent therapeutic breakthroughs have changed this paradigm, with KRAS inhibitors now emerging as viable treatment options. However, clinical responses have been highly variable across different tumor types, raising important questions about how best to use these therapies in precision oncology.
Problem Statement
KRAS mutation status alone is insufficient to predict response to KRAS-targeted therapies, limiting their effectiveness when applied without broader biological context.
Summary
This perspective highlights a fundamental shift in oncology thinking: mutation is not enough—context defines response. Although KRAS inhibitors represent a major therapeutic advance, their inconsistent efficacy across cancers underscores the complexity of tumor biology.
The article proposes a multidimensional framework that integrates several critical layers beyond KRAS mutation status. These include the tissue of origin, co-existing genetic alterations, downstream signaling pathways, and the tumor immune microenvironment. Together, these factors influence how tumors respond to KRAS inhibition.
The key implication is that precision oncology must evolve from a single-mutation approach to a context-driven strategy. This has direct relevance for clinical practice and research, including better patient selection, improved biomarker development, and more rational clinical trial design.
Ultimately, the paper emphasizes that the future of targeted therapy lies not just in identifying mutations, but in understanding the biological ecosystem in which those mutations operate.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.